David M Hyman
Overview
Explore the profile of David M Hyman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
174
Citations
19096
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Connolly R, Wang V, Hyman D, Grivas P, Mitchell E, Wright J, et al.
Clin Cancer Res
. 2024 Mar;
30(7):1273-1280.
PMID: 38433347
Purpose: NCI-MATCH assigned patients with advanced cancer and progression on prior treatment, based on genomic alterations in pretreatment tumor tissue. Arm J (EAY131-J) evaluated the combination of trastuzumab/pertuzumab (HP) across...
2.
Shrestha Bhattarai T, Shamu T, Gorelick A, Chang M, Chakravarty D, Gavrila E, et al.
Nat Commun
. 2022 Apr;
13(1):2111.
PMID: 35440569
AKT- a key molecular regulator of PI-3K signaling pathway, is somatically mutated in diverse solid cancer types, and aberrant AKT activation promotes altered cancer cell growth, survival, and metabolism. The...
3.
Rosen E, Won H, Zheng Y, Cocco E, Selcuklu D, Gong Y, et al.
Nat Commun
. 2022 Apr;
13(1):1936.
PMID: 35383193
No abstract available.
4.
Rosen E, Won H, Zheng Y, Cocco E, Selcuklu D, Gong Y, et al.
Nat Commun
. 2022 Mar;
13(1):1450.
PMID: 35304457
The efficacy of the highly selective RET inhibitor selpercatinib is now established in RET-driven cancers, and we sought to characterize the molecular determinants of response and resistance. We find that...
5.
Wang E, Mi X, Thompson M, Montoya S, Notti R, Afaghani J, et al.
N Engl J Med
. 2022 Feb;
386(8):735-743.
PMID: 35196427
Background: Covalent (irreversible) Bruton's tyrosine kinase (BTK) inhibitors have transformed the treatment of multiple B-cell cancers, especially chronic lymphocytic leukemia (CLL). However, resistance can arise through multiple mechanisms, including acquired...
6.
LeNoue-Newton M, Chen S, Stricker T, Hyman D, Blauvelt N, Bedard P, et al.
Clin Cancer Res
. 2022 Feb;
28(10):2118-2130.
PMID: 35190802
Purpose: We wanted to determine the prognosis and the phenotypic characteristics of hormone receptor-positive advanced breast cancer tumors harboring an ERBB2 mutation in the absence of a HER2 amplification. Experimental...
7.
Donoghue M, Schram A, Hyman D, Taylor B
Nat Cancer
. 2022 Feb;
1(8):774-783.
PMID: 35122052
The molecular characterization of tumors now informs clinical cancer care for many patients. This advent of molecular oncology has been driven by the expanding number of therapeutic biomarkers that can...
8.
Hyman D, Tran B, Paz-Ares L, Machiels J, Schellens J, Bedard P, et al.
JCO Precis Oncol
. 2022 Feb;
3:1-13.
PMID: 35100734
Purpose: Concurrent PIK3CA mutations and fibroblast growth factor receptor (FGFR) alterations occur in multiple cancer types, including estrogen receptor-positive breast cancer, bladder cancer, and endometrial cancer. In this first-in-human combination...
9.
Srinivasan P, Bandlamudi C, Jonsson P, Kemel Y, Chavan S, Richards A, et al.
Nat Genet
. 2021 Nov;
53(11):1577-1585.
PMID: 34741162
Human cancers arise from environmental, heritable and somatic factors, but how these mechanisms interact in tumorigenesis is poorly understood. Studying 17,152 prospectively sequenced patients with cancer, we identified pathogenic germline...
10.
Smyth L, Reichel J, Tang J, Patel J, Meng F, Selcuklu D, et al.
JCO Precis Oncol
. 2021 Jul;
5.
PMID: 34250397
Purpose: Cell-free DNA (cfDNA) analysis offers a noninvasive means to access the tumor genome. Despite limited sensitivity of broad-panel sequencing for detecting low-frequency mutations in cfDNA, it may enable more...